Drug intelligence / Profile preview

IST-02

Development stage: Preclinical
Lead developer: Isterian Biotech
Modality: Small Molecules
Administration: Inhalation

Overview

IST-02 is a small molecule drug candidate developed by Isterian Biotech. It acts as an inhibitor of transglutaminase 2 (TGM2), also known as protein-glutamine gamma-glutamyltransferase. TGM2 is implicated in the pathogenesis of fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), due to its role in cross-linking proteins within the extracellular matrix and promoting tissue scarring. IST-02 is being investigated for its potential to treat IPF by inhibiting TGM2 activity and thereby reducing fibrosis. The compound is currently in preclinical development[1][3].

Targets

TGM2 (Tissue Transglutaminase 2)

Beyond the preview

Go deeper on IST-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IST-02.

Explore the full profile